There is tremendous research interest both on the industry side and from the NIH regarding IBS. This is an extremely common condition that is associated with significant impairment in quality of life and huge societal expense.Given that this is a heterogenous problem which we have not fully characterized, a "cure" for all IBS is not likely anytime soon. What will likely happen is that people will identify mechanisms of illness in subsets of IBS patients that will allow for effective therapy. The wheel sgrind slowly, but they are grinding.